Jaguar Health (NASDAQ: JAGX) and Foundation Medicine (NASDAQ:FMI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Risk and Volatility
Jaguar Health has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Foundation Medicine has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500.
11.7% of Jaguar Health shares are owned by institutional investors. Comparatively, 30.9% of Foundation Medicine shares are owned by institutional investors. 3.3% of Jaguar Health shares are owned by company insiders. Comparatively, 2.7% of Foundation Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Jaguar Health and Foundation Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Jaguar Health and Foundation Medicine, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jaguar Health currently has a consensus price target of $2.00, indicating a potential upside of 1,328.57%. Foundation Medicine has a consensus price target of $58.25, indicating a potential downside of 29.14%. Given Jaguar Health’s stronger consensus rating and higher probable upside, analysts clearly believe Jaguar Health is more favorable than Foundation Medicine.
Earnings and Valuation
This table compares Jaguar Health and Foundation Medicine’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jaguar Health||$140,000.00||90.83||-$14.73 million||($0.66)||-0.21|
|Foundation Medicine||$116.86 million||25.50||-$113.19 million||($4.47)||-18.39|
Jaguar Health has higher earnings, but lower revenue than Foundation Medicine. Foundation Medicine is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.
Jaguar Health beats Foundation Medicine on 9 of the 13 factors compared between the two stocks.
About Jaguar Health
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
About Foundation Medicine
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.